Archer Daniels gains 5% as accounting concerns fall despite weak results 📈

9:34 pm 12 March 2024

Shares of Chicago-based agriculture and nutrition giant Archer Daniels Midland (ADM.US) are gaining nearly 5% today, as the company announced that it has completed an internal investigation into the nutrition industry's accounting, where it identified accounting problems in January. Following this disclosure, the company's shares cheapened by more than 22% and recorded their weakest session since 1929 crash. Positive comments related to accounting problems, along with a better-than-forecast outlook for the future, increased Wall Street optimism and investors buy shares of the heavily oversold company, leading to almost 5% increases. 

  • Despite weakness in the 'Nutrition' sector, the segment is expected to bring the company mid-single-digit revenue growth and operating income, which is expected to be higher in 2024 than in 2023.
  • Profit forecasts appealed to Wall Street - the company expects adjusted earnings per share in 2024 of $5.25-$6.25, compared to $5.41 estimates from analysts surveyed by FactSet.
  • Management has approved an additional $2 billion share buyback. The market expects the company may have the worst behind it. The company said it is aiming for sharp improvements in earnings reporting, as well as the overall profitability of its operations and supply chain. 
  • Sales in the fourth quarter fell 11% year-on-year, and earnings per share fell from 30% year-on-year. Margins also fell however investors, are hopeful that the company will buy back more shares in 2024 after the stock hit a record high since 2008.
  • The company anticipates soybean crush margin will decline this year, likely moving into a range of $35/metric ton (MT) to $60/MT. Q4 profit included net charges of $171 million, and Archer expectes FY 2024 $5.87 earnings per share.

Weak results not enough to make Archer shares cheap?

  • The company reported net income of $565 million, or $1.06 per share, in Q4 2023, compared to $1.019 billion, or $1.84 per share, in Q4 2022. Adjusted for a $0.3 impairment and restructuring charge, earnings were $1.36, slightly below FactSet forecasts of $1.43.
  • Revenue came in 3% below forecasts, falling to $22.978 billion vs. $25.939 billion in 2022, below FactSet forecasts of $23.786 billion. The nutrition segment reported an operating loss of $10 million in Q4, compared to a profit of $105 million in Q4 2022.
  • CFRA analysts raised their target price for the stock to $67 from $61 previously, arguing the decision was due to the normalization of the commodity market, following a series of supply chain disruptions, and less-than-expected uncertainty related to the impact of the 'Nutrition' segment's accounting scandal, where the company reported overstated earnings for several quarters, at a time when management was tying higher bonuses to the sector's performance.
  • CFRA expects 2024 to be a lagging hole for the company in terms of its earnings growth outlook, as the company stressed confidence in the 2025 financial targets it set three years ago. Accounting issues are likely to prove to have much less of an impact than feared, which has the potential to remove a serious overhang on the company's shares.
  • The company has created a stronger team and hired managers with experience in supply chain management. It has engaged experts to identify opportunities to streamline operations at its largest plants and simplify product and production lines.

Archer Daniels Midland (ADM.US), D1 interval

The company's shares reached the SMA50 (orange line) today, where a bit of broader supply was triggered, halting today's rebound.

Source: xStation5

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world.